Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 5/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27014168 | 0.78 | SRD5A1 (0.41) | NAMPTSRD5A1HTR1AIDO1KDM5A | |
| SCHEMBL27014163 | 0.78 | SRD5A1 (0.41) | NAMPTSRD5A1HTR1AIDO1KDM5A | |
| SCHEMBL25079090 | 0.73 | NAMPT (0.38) | NAMPTSRD5A1HTR1ACYP2D6DRD2 | |
| SCHEMBL16363092 | 0.68 | SRD5A1 (0.45) | SRD5A1HTR1AIDO1TRPV1DRD2 | |
| SCHEMBL1745527 | 0.68 | SRD5A1 (0.45) | SRD5A1HTR1AIDO1TRPV1DRD2 | |
| SCHEMBL16363081 | 0.68 | SRD5A1 (0.45) | SRD5A1HTR1AIDO1TRPV1DRD2 | |
| SCHEMBL8710061 | 0.66 | SRD5A1 (0.45) | SRD5A1HTR1ACYP2D6IDO1DRD2 | |
| SCHEMBL4119987 | 0.65 | CNR2 (0.43) | IDO1 | |
| SCHEMBL4119991 | 0.65 | CNR2 (0.43) | IDO1 | |
| SCHEMBL4119985 | 0.65 | CNR2 (0.43) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | PINK1, NME4, AK2 | NAMPT 129/4885SRD5A1 4075/4885HTR1A 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.